POTOMAC, MD — February 17, 2026 — Leads & Copy — IGC Pharma, Inc. (NYSE American:IGC) has received a Notice of Allowance from the Canadian Intellectual Property Office (CIPO) for its proprietary composition underlying IGC-AD1, a Phase 2 clinical stage program targeting agitation associated with Alzheimer’s disease.
Patent No. 3,095,729, titled “Method and Composition for Treating CNS Disorders”, secures composition protection for IGC-AD1 across key North American jurisdictions. According to the company, this reinforces long-term exclusivity around the formulation as the Phase 2 CALMA trial progresses toward enrollment completion.
The protection covers the specific low-dose combination central to IGC-AD1’s therapeutic strategy, according to the company.
IGC Pharma recently reported that approximately 70% of the planned enrollment in the ongoing randomized, double-blind, placebo-controlled Phase 2 CALMA trial has been completed.
The company believes that strengthening composition protection at this stage enhances both the durability and commercial positioning of IGC-AD1 as the program advances towards enrollment completion and subsequent database lock.
Ram Mukunda, CEO of IGC Pharma, stated that securing composition protection across North America strengthens the strategic foundation of IGC-AD1 at an important stage of clinical development. He added that as CALMA progresses toward its final enrollment phase, expanding patent coverage enhances both the durability and long-term commercial positioning of the Alzheimer’s program and supports its potential commercial differentiation.
IGC-AD1 is a proprietary formulation that uses low doses of tetrahydrocannabinol (THC) combined with other ingredients. The company believes that the multi-target formulation is differentiated from single-target therapeutic approaches as regulatory frameworks for cannabinoid-based therapeutics continue to evolve.
IGC Pharma (NYSE American:IGC) is a clinical-stage biotechnology company leveraging AI to develop treatments for Alzheimer’s and metabolic disorders. The lead asset, IGC-AD1, is a cannabinoid-based therapy in a Phase 2 trial (CALMA) for agitation in Alzheimer’s dementia. The pipeline includes TGR-63, targeting amyloid plaques, and early-stage programs focused on neurodegeneration, tau proteins, and metabolic dysfunctions. The company integrates AI to accelerate drug discovery, optimize clinical trials, and enhance patient targeting and has a complete patent portfolio.
Source: IGC Pharma
